Golimumab (anti-TNF Monoclonal Antibody): Where We Stand Today

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2020 Dec 28

PMID 33369527

Citations 11

Authors

Ana Teresa Melo

Raquel Campanilho-Marques

Joao Eurico Fonseca

Affiliations

Soon will be listed here.

Abstract

Tumor necrosis factor (TNF) is a pro-inflammatory cytokine and its overexpression has been implicated in the pathophysiology of several chronic immune-mediated inflammatory diseases. Biological therapies, like TNF inhibitors, have been revolutionizing the course of these disorders. Golimumab is a transgenic anti-TNF monoclonal antibody that acts primarily by targeting and neutralizing TNF, thus preventing inﬂammation. It is approved for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Nonradiographic axial Spondyloarthritis, Juvenile Idiopathic Arthritis, and Ulcerative Colitis. Clinical trials are also being conducted in other conditions. This review charts the clinical development of golimumab and outlines the data that support its potential use across several Immune-mediated inflammatory diseases.

Citing Articles

Inflammatory Pseudotumor of the Spleen in a Patient With Psoriatic Arthritis: A Diagnostic Challenge in the COVID-19 Era.

Iliadis A, Koletsa T, Vounotrypidis P, Fassas A, Apostolidis A, Apostolidis S Cureus. 2024; 16(11):e73121.

PMID: 39651014 PMC: 11622730. DOI: 10.7759/cureus.73121.

Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective.

Heidari A, Ghane Y, Heidari N, Hosseini S, Goodarzi A Ther Adv Chronic Dis. 2024; 15:20406223241257342.

PMID: 38827348 PMC: 11143857. DOI: 10.1177/20406223241257342.

Early identification of golimumab-treated patients with higher likelihood of long-term retention.

Garcia-Dorta A, Gonzalez-Davila E, Sanchez-Jareno M, Cea-Calvo L, Pombo-Suarez M, Sanchez-Alonso F Front Immunol. 2024; 15:1359571.

PMID: 38680482 PMC: 11046487. DOI: 10.3389/fimmu.2024.1359571.

Patient self-reported experience and satisfaction with golimumab and etanercept treatments for rheumatic diseases: A cohort study.

Xia W, Zhou L, Gao W, Zhang Y, Si F, Bai F Medicine (Baltimore). 2024; 103(8):e36982.

PMID: 38394542 PMC: 11309713. DOI: 10.1097/MD.0000000000036982.

Research progress of targeted therapy regulating Th17/Treg balance in bone immune diseases.

Wang X, Sun B, Wang Y, Gao P, Song J, Chang W Front Immunol. 2024; 15:1333993.

PMID: 38352872 PMC: 10861655. DOI: 10.3389/fimmu.2024.1333993.

References

Mok C, Li O, Chan K, Ho L, Hui P . Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial. Scand J Rheumatol. 2015; 44(6):480-6. DOI: 10.3109/03009742.2015.1038300. View

Sieper J, van der Heijde D, Dougados M, Maksymowych W, Scott B, Boice J . A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015; 67(10):2702-12. PMC: 4755041. DOI: 10.1002/art.39257. View

Le Blay P, Mouterde G, Barnetche T, Morel J, Combe B . Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. J Rheumatol. 2012; 39(4):712-5. DOI: 10.3899/jrheum.110982. View

Brunner H, Ruperto N, Tzaribachev N, Horneff G, Chasnyk V, Panaviene V . Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2017; 77(1):21-29. PMC: 5754736. DOI: 10.1136/annrheumdis-2016-210456. View

Pelechas E, Voulgari P, Drosos A . Golimumab for Rheumatoid Arthritis. J Clin Med. 2019; 8(3). PMC: 6463251. DOI: 10.3390/jcm8030387. View

Sepriano A, Regel A, van der Heijde D, Braun J, Baraliakos X, Landewe R . Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017; 3(1):e000396. PMC: 5278329. DOI: 10.1136/rmdopen-2016-000396. View

Mantravadi S, Ogdie A, Kraft W . Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol. 2017; 10(8):899-910. PMC: 6348387. DOI: 10.1080/17512433.2017.1329009. View

Kavanaugh A, Husni M, Harrison D, Kim L, Lo K, Leu J . Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study. Arthritis Rheumatol. 2017; 69(11):2151-2161. PMC: 5765449. DOI: 10.1002/art.40226. View

DeHoratius R, Brent L, Curtis J, Ellis L, Tang K . Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept. Patient. 2018; 11(3):361-369. PMC: 5948248. DOI: 10.1007/s40271-018-0297-5. View

10.

Greener T, Boland K, Steinhart A, Silverberg M . The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn's Disease. J Crohns Colitis. 2018; 12(4):458-464. DOI: 10.1093/ecco-jcc/jjx176. View

11.

Martineau C, Flourie B, Wils P, Vaysse T, Altwegg R, Buisson A . Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. Aliment Pharmacol Ther. 2017; 46(11-12):1077-1084. DOI: 10.1111/apt.14371. View

12.

Olesen C, Coskun M, Peyrin-Biroulet L, Nielsen O . Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol Ther. 2016; 159:110-9. DOI: 10.1016/j.pharmthera.2016.01.001. View

13.

Castro-Laria L, Arguelles-Arias F, Garcia-Sanchez V, Manuel Benitez J, Fernandez-Perez R, Trapero-Fernandez A . Initial experience with golimumab in clinical practice for ulcerative colitis. Rev Esp Enferm Dig. 2016; 108(3):129-32. DOI: 10.17235/reed.2016.4068/2015. View

14.

Rutgeerts P, Feagan B, Marano C, Padgett L, Strauss R, Johanns J . Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015; 42(5):504-14. PMC: 4755132. DOI: 10.1111/apt.13291. View

15.

Dragoni G, Le Grazie M, Orlandini B, Rogai F . Golimumab in inflammatory bowel diseases: present and future scenarios. Clin J Gastroenterol. 2018; 12(1):1-9. DOI: 10.1007/s12328-018-0906-9. View

16.

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

17.

Maxwell L, Zochling J, Boonen A, Singh J, Veras M, Tanjong Ghogomu E . TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015; (4):CD005468. PMC: 11200207. DOI: 10.1002/14651858.CD005468.pub2. View

18.

Vieira-Sousa E, Alves P, Rodrigues A, Teixeira F, Tavares-Costa J, Bernardo A . GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Ann Rheum Dis. 2020; 79(4):490-498. PMC: 7147178. DOI: 10.1136/annrheumdis-2019-216500. View

19.

Segaert S, Hermans C . Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents. Am J Clin Dermatol. 2017; 18(6):771-787. DOI: 10.1007/s40257-017-0296-7. View

20.

Godfrey M, Friedman L . Tuberculosis and Biologic Therapies: Anti-Tumor Necrosis Factor-α and Beyond. Clin Chest Med. 2019; 40(4):721-739. DOI: 10.1016/j.ccm.2019.07.003. View